Quick Answer
NovaBridge Biosciences reported Operating Income Loss of -$51.43 million for the year ending 2024.
- NovaBridge Biosciences showed an increase of +28.6% in Operating Income Loss from 2023 to 2024.
- This data is from NovaBridge Biosciences's annual report (Form 10-K), filed with the SEC on April 3, 2025.
- XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2022 to 2024), NovaBridge Biosciences's Operating Income Loss has grown by 3.1%.
- Historical annual values: Fiscal year 2024: -$51.43 million | Fiscal year 2023: -$72.02 million | Fiscal year 2022: -$53.08 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: